Comment: Alteplase for Acute Myocardial Infarction

Abstract

Get full access to this article

View all access options for this article.

References

Verstraete

Bernard

Bory

. Randomized trial of intravenous recombinant tissue-type plasminogen activator versus intravenous streptokinase in acute myocardial infarction. Lancet 1985; 1: 842–7.

Chesebro

Knatterud

Roberts

. Thrombolysis in myocardial infarction (TIMI) trial, phase I: A comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Circulation 1987; 76: 142–54.

White

Norris

Brown

. Effect of intravenous streptokinase on left ventricular function and early survival after acute myocardial infarction. N Engl J Med 1987; 317: 850–5.

ISAM Study Group. A prospective trial of intravenous streptokinase in acute myocardial infarction (ISAM). Mortality, morbidity and infarct size at 21 days. N Engl J Med 1986; 314: 1465–71.

Guerci

Gerstenblith

Brinker

. A randomized trial of intravenous tissue plasminogen activator for acute myocardial infarction with subsequent randomization to elective coronary angioplasty. N Engl J Med 1987; 317: 1613–8.

Gruppo Italiano per lo Studio Della Streptochinasi Nell'Infarcto Miocardio (GISSI). Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Lancet 1986; 1: 397–401.

Sherry

. Appraisal of various thrombolytic agents in the treatment of acute myocardial infarction. Am J Med 1987; 83 (suppl 2A): 31–46.